CarsonAllaria Wealth Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

CarsonAllaria Wealth Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-195	Closed	-$593	–	377
2024 Q4	$593	Hold	195	–	–	﹤0.01%	338
2024 Q3	$1.01K	Hold	195	–	–	﹤0.01%	363
2024 Q2	$501	Hold	195	–	–	﹤0.01%	364
2024 Q1	$959	Hold	195	–	–	﹤0.01%	368
2023 Q4	$1.71K	Hold	195	–	–	﹤0.01%	310
2023 Q3	$2.24K	Hold	195	–	–	﹤0.01%	298
2023 Q2	$4.93K	Hold	195	–	–	﹤0.01%	266
2023 Q1	$6.28K	Hold	195	–	–	0.01%	245
2022 Q4	$4K	Hold	195	–	–	﹤0.01%	256
2022 Q3	$5K	Buy	+195	New	+$3.96K	﹤0.01%	232

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

CarsonAllaria Wealth Management's RVNC Position: Q1 2025 in Review

CarsonAllaria Wealth Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 195 shares — an estimated $593 sold.

CarsonAllaria Wealth Management first reported a position in RVNC in Q3 2022 and held it in 10 quarters. The position peaked at $6.28K in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

CarsonAllaria Wealth Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
CarsonAllaria Wealth Management sold 195 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $593.
CarsonAllaria Wealth Management first reported a position in Revance Therapeutics, Inc. in Q3 2022 and held it in 10 quarters.
CarsonAllaria Wealth Management's Revance Therapeutics, Inc. position peaked at $6.28K in Q1 2023.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on CarsonAllaria Wealth Management's 13F filing for Q1 2025, filed 28 Apr 2025.